Viromed H1 FY26 net loss widens to €1.1 million; revenue rises 4.17% to €2.5 million
Bitget2026/09/28 10:31- Viromed Medical posted H1 2026 revenue of €2.5 million, up 4.17% from a year earlier.
- Net loss widened to €1.1 million from €0.8 million a year earlier.
- Equity climbed 43.9% to €9.5 million, lifting the equity ratio to 67.6% from 39.9%.
- Management attributed the earnings trend to expenses for the PulmoPlas study and ViroCAP med approval and launch.
- Confirmed full-year 2026 guidance for a significant increase in revenue and net income; ViroCAP med sales started in July.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
